Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF EBIT

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF (GERM) currently reports a EBIT of $240M as of September 2026. That compares with $520M in the prior-year period — down 54.8% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's EBIT history and peer comparisons.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's EBIT decreased from $520M to $240M — a 54.8% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's EBIT of $240M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF reported $240M in EBIT as of September 2026. That compares with $520M in the prior-year period — down 54.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $240M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF, and consider following GERM for alerts when major investors trade the stock.